Alterity Therapeutics Secures U.S. Patent for ATH434 Until 2045 — ALTERITY THERAPEUTICS LIMITED

Event summary

Alterity Therapeutics received a new U.S. composition of matter patent for ATH434, extending protection until at least 2045.
The patent covers the crystalline structure of ATH434 mesylate and methods for treating neurological conditions.
ATH434 is Alterity's lead clinical asset targeting Multiple System Atrophy (MSA) and Parkinson’s disease.
Alterity plans to initiate Phase 3 trials for MSA by year-end 2026.

The big picture

The new patent significantly enhances the long-term commercial potential of ATH434, reinforcing Alterity's strategic position in the neurodegenerative disease space. This intellectual property milestone comes as the company prepares to initiate pivotal Phase 3 trials for MSA, a rare and rapidly progressive condition with no approved disease-modifying treatments. The extended protection also opens doors for future development in Parkinson’s disease, a larger market opportunity.

What we're watching

Clinical Development: The pace at which Alterity advances ATH434 through Phase 3 trials in MSA will determine its commercial viability.
Market Expansion: Whether the strengthened IP protection enables Alterity to secure partnerships for developing ATH434 in Parkinson’s disease and other neurodegenerative disorders.
Regulatory Strategy: How the inclusion of ATH434 in the FDA’s Orange Book upon approval will impact its market exclusivity and competitive positioning.